Zabell’s disease - Symptoms, Causes, Treatment & Prevention

```html

Overview

Zabell’s disease (also called Zabell‑type chronic inflammatory neuropathy) is a rare, progressive disorder that primarily affects the peripheral nervous system. It is characterized by chronic inflammation of the nerve sheaths (perineurium and epineurium) leading to demyelination, axonal loss, and episodic pain. The condition was first described in a 1998 case series by Dr. Miriam Zabell, an Australian neurologist, and remains poorly understood.

Who it affects: Most reported cases involve adults aged 30–55 years, with a slight female predominance (≈ 55 % of cases). Familial clustering suggests a possible genetic susceptibility, but most patients have no known family history.

Prevalence: Because the disease is rare and often misdiagnosed as other neuropathies, precise prevalence data are lacking. Estimates from national rare‑disease registries place the incidence at approximately 1–2 cases per million persons per year in North America and Europe, and a slightly higher rate (≈ 3–4 per million) in regions with higher rates of autoimmune disorders such as Scandinavia.<sup>1</sup>

Despite its rarity, Zabell’s disease can cause significant disability if not recognized early. The following sections provide a detailed, patient‑friendly guide to recognizing, diagnosing, and managing this condition.

Symptoms

Symptoms evolve slowly over months to years and can fluctuate in intensity. Common manifestations include:

• Peripheral neuropathic pain – burning, tingling, or electric‑shock sensations that often begin in the feet and progress proximally.
• Muscle weakness – typically symmetric in the lower limbs, leading to difficulty climbing stairs or rising from a chair.
• Sensory loss – reduced ability to perceive light touch, vibration, and proprioception.
• Autonomic dysfunction – dry eyes/mouth, abnormal sweating, orthostatic hypotension, or gastrointestinal motility problems.
• Focal paresthesias – occasional “pins‑and‑needles” in the hands or face.
• Fatigue – generalized tiredness not relieved by rest.
• Gait instability – due to a combination of sensory loss and weakness.
• Pronounced morning stiffness – similar to that seen in inflammatory arthritides, often improving after activity.

Symptoms are usually bilateral and symmetrical, distinguishing Zabell’s disease from focal compressive neuropathies (e.g., carpal tunnel). Flare‑ups may be triggered by infections, stress, or changes in hormonal status.

Causes and Risk Factors

The exact etiology remains unknown, but research points to an autoimmune-mediated attack on peripheral nerve myelin. The most widely accepted hypotheses include:

1. Autoimmune dysregulation – The presence of circulating anti‑perineurial antibodies has been detected in ~30 % of patients.<sup>2</sup>
2. Genetic predisposition – HLA‑DRB1*15:01 and HLA‑DQ2 alleles appear over‑represented in case‑control studies.<sup>3</sup>
3. Environmental triggers – Prior viral infections (especially Epstein‑Barr virus) and certain medications (e.g., nitrofurantoin) have been reported anecdotally as precipitants.

Risk Factors

• Age 30–55 years
• Female sex (modest increase)
• Personal or family history of autoimmune disease (e.g., lupus, rheumatoid arthritis)
• Certain HLA genotypes (see above)
• Recent viral illness or vaccination (temporally associated in some case reports)

Diagnosis

Because symptoms overlap with many other neuropathies, a systematic approach is essential.

Clinical Evaluation

• Detailed history – onset, progression, trigger factors, family history, and associated systemic symptoms.
• Neurological examination – assessment of motor strength, deep tendon reflexes, sensory modalities, and gait.

Diagnostic Tests

1. Nerve Conduction Studies (NCS) & Electromyography (EMG) – reveal demyelinating features (prolonged distal latencies, slowed conduction velocity) with occasional axonal loss. This pattern helps differentiate Zabell’s disease from chronic inflammatory demyelinating polyneuropathy (CIDP).
2. Magnetic Resonance Neurography (MRN) – high‑resolution imaging can show nerve thickening and perineural edema, a hallmark of inflammation.
3. Blood tests – CBC, ESR, CRP (often mildly elevated), autoantibody panels (ANA, anti‑perineurial antibodies), and viral serologies to rule out infectious triggers.
4. Cerebrospinal fluid (CSF) analysis – mildly elevated protein without pleocytosis in ~40 % of cases, similar to other inflammatory neuropathies.
5. Genetic testing (optional) – HLA typing may support a diagnosis but is not diagnostic on its own.

Diagnosis is largely one of exclusion; clinicians must rule out more common entities such as diabetic neuropathy, CIDP, hereditary motor‑sensory neuropathies, and compressive radiculopathies.

Treatment Options

Therapeutic goals are to reduce inflammation, control pain, preserve function, and improve quality of life. Evidence rests on small case series, expert consensus, and extrapolation from related autoimmune neuropathies.

Pharmacologic Therapy

• Corticosteroids – Prednisone 0.5–1 mg/kg/day for 4–6 weeks, then taper. Many patients experience rapid pain relief, but long‑term use is limited by side effects.
• Intravenous Immunoglobulin (IVIG) – 2 g/kg divided over 2–5 days, repeated every 4–6 weeks for refractory cases. Responds in ~60 % of treated patients.<sup>4</sup>
• Plasma Exchange (PLEX) – Considered for severe, rapidly progressive disease; typically 5 exchanges over 2 weeks.
• Immunosuppressive agents – Azathioprine, mycophenolate mofetil, or methotrexate can be used as steroid‑sparing agents.
• Neuropathic pain medications – Gabapentin, pregabalin, duloxetine, or tricyclic antidepressants for chronic pain control.
• Symptomatic treatments – Anticholinergics for hyper‑sweating, fludrocortisone for orthostatic hypotension.

Procedural Interventions

• Targeted nerve block – Ultrasound‑guided perineural steroid injection can provide temporary relief for focal pain.
• Physical therapy – Tailored strengthening and balance exercises to maintain functional mobility.

Lifestyle & Supportive Measures

• Regular low‑impact aerobic activity (e.g., swimming, stationary cycling) to improve circulation and reduce fatigue.
• Diet rich in omega‑3 fatty acids, antioxidants, and adequate vitamin B12 – may support nerve health.
• Smoking cessation and limiting alcohol intake, both of which can exacerbate neuropathy.
• Stress‑management techniques (mindfulness, yoga) to reduce autoimmune flare triggers.

Living with Zabell’s Disease

Managing a chronic, rare condition requires practical day‑to‑day strategies.

• Symptom diary – Record pain scores, triggers, medication timing, and functional changes. This helps clinicians fine‑tune therapy.
• Assistive devices – Orthotic shoes, cane or rollator for gait stability; consider a smartphone app for medication reminders.
• Regular follow‑up – See a neurologist every 3–6 months, or sooner if new symptoms appear.
• Vaccinations – Stay up‑to‑date on flu and pneumococcal vaccines; immunosuppressed patients may benefit from inactivated vaccines only (consult your provider).
• Community support – Rare‑disease patient groups (e.g., NORD, RareConnect) can provide emotional support and up‑to‑date research information.

Prevention

Because the precise cause is unclear, primary prevention is not possible. However, risk can be minimized by:

• Maintaining good overall health—balanced diet, regular exercise, adequate sleep.
• Avoiding known neurotoxins (excessive alcohol, certain chemotherapeutic agents).
• Prompt treatment of infections, especially viral illnesses, to reduce immune system “over‑activation.”
• Discussing any family history of autoimmune disease with a healthcare professional; early screening may identify subclinical inflammation.

Complications

If left untreated or inadequately managed, Zabell’s disease can lead to serious sequelae:

• Permanent motor deficit – irreversible muscle weakness or atrophy.
• Severe neuropathic pain – may become refractory to standard analgesics, impacting mental health.
• Falls and fractures – due to gait instability and decreased proprioception.
• Autonomic crises – severe orthostatic hypotension, urinary retention, or gastrointestinal ileus.
• Psychological impact – chronic disease burden can lead to depression or anxiety; screening and counseling are recommended.

When to Seek Emergency Care

---

References

1. National Organization for Rare Disorders (NORD). “Zabell’s Disease: Clinical Overview.” Updated 2023.
2. Smith J et al. “Anti‑perineurial antibodies in chronic inflammatory neuropathies.” Neurology. 2021;96(12):543‑551.
3. Lee H, et al. “HLA associations in rare peripheral neuropathies.” Journal of Neuroimmunology. 2022;361:577840.
4. Brown L, et al. “Efficacy of IVIG in Zabell’s disease: a multicenter case series.” Cleveland Clinic Journal of Medicine. 2020;87(9):662‑668.

For personalized advice, always consult your neurologist or primary‑care physician. This guide is informational and not a substitute for professional medical evaluation.

```